CymaBay Therapeutics Inc (USD)
CBAY
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range1.64 | 1.73
52-Wk Range1.29 | 14.00
Last Close1.66
Mkt Cap (m)114.04
Dividend yield-
ISINUS23257D1037
Volume1,364,248
Exchange VenueNAS

Company Profile

CymaBay Therapeutics Inc is an American biotechnology enterprise. Its product candidates include Arhalofenate, MBX-8025, and MBX-2982, which are meant to combat serious metabolic diseases.

Key Information
Price/Earning-
Price/Book0.54
Price/Sales-
P/CF-
Rev Growth (3 year avg)0.00
EPS Growth (3 year avg)-
Operating Margin % -
Net Margin %-
Return on Equity-56.82
Debt/Equity-

Legal Documents

Prospectus
en 06/03/2019
Annual Report
en 31/12/2018

Financials

Income Statement
USD201320142015201620172018
Revenue (m)10
Operating Income (m)-9-24-26-26-21-73
Net Income (m)-10-32-16-27-28-73
Basic EPS17.35-2.65-0.82-1.14-0.79-1.25
Avg. Diluted Shares Outstanding (m)141219233558
Balance Sheet
USD201320142015201620172018
Current Assets (m)32374319104182
Non Current Assets (m)115
Total Assets (m)33374319104187
Current Liabilities (m)920691614
Total Liabilities (m)------
Total Equity (m)191428485170
Cash Flows
USD201320142015201620172018
Operating Cash Flows (m)-8-21-23-23-20-55
Capital Expenditure (m)---1
Figures are quoted in USD unless stated otherwise
0.04 (2.41%)
$
1.70
Last Price